Surface recognition of proteins provides access to new therapeutic and diagnostic strategies. In our proposed research we will target helix-cleft protein-protein interactions such as p53-HDM2 using gold nanoparticle-based synthetic receptors. In these receptors, the nanoparticle monolayer will play an active role in the recognition process, exploiting the size scale (6-10 nm in diameter) and the ability of nanoparticles to be templated to target molecules. We will pursue two different strategies in our research: 1) Presentation of helices for the targeting of complementary protein clefts (e.g. HDM2); 2) Templation of the nanoparticles to helices for recognition of exposed helices. The proposed research features three specific Aims.
These aims are interrelated, bringing to bear synthetic, physical and biophysical methodologies. In these Aims, we will:
Aim 1 : Determine the scope and events involved in electrostatic binding of nanoparticles and their templation to ?-helices, focusing on the optimization of helix recognition.
Aim 2 : Covalently link the supramolecular peptide-particle assemblies developed in Aim 1, and target these conjugates to cleft-bearing proteins, including the p-53 binding domain of HDM2. These studies will focus on: 1) The ability of the particle to stabilize the helical structure of the peptide; 2) The use of the particle monolayer to enhance the affinity of the receptors and to control the structure of the bound protein.
Aim 3 : Use nanoparticles as sensors for biomedically-relevant proteins. In these studies, particles will be templated to fluorophore-tagged peptides. The complexation of the peptide by the particle will quench the fluorophore. Fluorescent enhancement upon displacement of the peptide by the target protein will then be used to transduce binding. The selectivity of the protein-particle binding process will be applied in an array format to provide """"""""chemical nose"""""""" sensing of proteins. Relevance: This research focuses on the creation of potential anti-cancer therapeutics and the detection of protein biomarkers for diagnosis of cancer and other disease states. ? ? ?
| Gupta, Akash; Mumtaz, Shazia; Li, Cheng-Hsuan et al. (2018) Combatting antibiotic-resistant bacteria using nanomaterials. Chem Soc Rev : |
| Gupta, Akash; Das, Riddha; Yesilbag Tonga, Gulen et al. (2018) Charge-Switchable Nanozymes for Bioorthogonal Imaging of Biofilm-Associated Infections. ACS Nano 12:89-94 |
| Kelly, Christopher; Tullius, Ryan; Lapthorn, Adrian J et al. (2018) Chiral Plasmonic Fields Probe Structural Order of Biointerfaces. J Am Chem Soc 140:8509-8517 |
| Zhu, Dong Yu; Landis, Ryan F; Li, Cheng-Hsuan et al. (2018) Dynamically crosslinked polymer nanocomposites to treat multidrug-resistant bacterial biofilms. Nanoscale 10:18651-18656 |
| Jiang, Ying; Hardie, Joseph; Liu, Yuanchang et al. (2018) Nanocapsule-mediated cytosolic siRNA delivery for anti-inflammatory treatment. J Control Release 283:235-240 |
| Ray, Moumita; Lee, Yi-Wei; Hardie, Joseph et al. (2018) CRISPRed Macrophages for Cell-Based Cancer Immunotherapy. Bioconjug Chem 29:445-450 |
| Landis, Ryan F; Li, Cheng-Hsuan; Gupta, Akash et al. (2018) Biodegradable Nanocomposite Antimicrobials for the Eradication of Multidrug-Resistant Bacterial Biofilms without Accumulated Resistance. J Am Chem Soc 140:6176-6182 |
| Luther, D C; Lee, Y W; Nagaraj, H et al. (2018) Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Expert Opin Drug Deliv 15:905-913 |
| Scaletti, Federica; Hardie, Joseph; Lee, Yi-Wei et al. (2018) Protein delivery into cells using inorganic nanoparticle-protein supramolecular assemblies. Chem Soc Rev 47:3421-3432 |
| Landis, Ryan F; Gupta, Akash; Lee, Yi-Wei et al. (2017) Cross-Linked Polymer-Stabilized Nanocomposites for the Treatment of Bacterial Biofilms. ACS Nano 11:946-952 |
Showing the most recent 10 out of 150 publications
